ARVN

Arvinas Stock Price

65.67
1.83 (2.87%)
Upgrade to Real-Time
Regular Market
65.67

Low
19.68

52 Week Range

High
92.77

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Arvinas Inc ARVN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.83 2.87% 65.67 10:08:33
Open Price Low Price High Price Close Price Prev Close
64.06 63.83 65.73 63.84
Bid Price Ask Price Spread News
65.01 65.85 0.84 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
152 12,217 $ 64.41 $ 786,910 326,157 19.68 - 92.77
Last Trade Time Type Quantity Stock Price Currency
10:09:44 20 $ 65.19 USD

Arvinas Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.22B 48.99M 38.16M $ 21.80M $ - -3.01 -19.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 396.81k 2.80%

more financials information »

Arvinas News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ARVN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week63.5865.7356.638362.51349,3942.093.29%
1 Month63.4773.3056.638365.40329,9662.203.47%
3 Months78.8781.4356.5967.92403,234-13.20-16.74%
6 Months25.1692.7722.790164.72798,09040.51161.01%
1 Year43.0092.7719.6851.20642,48722.6752.72%
3 Years21.0092.7710.1944.13393,52844.67212.71%
5 Years21.0092.7710.1944.13393,52844.67212.71%

Arvinas Description

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases.


Your Recent History
NASDAQ
ARVN
Arvinas
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.